---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: VX19-147-101"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: VX19-147-101. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 71 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence/vx19-147-101"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: VX19-147-101

<a id="heading-3.1.2"></a>

## 3.1.2 VX19-147-101

<a id="heading-3.1.2.1"></a>

### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

#### Purpose stated in the ClinicalTrials.gov brief summary

> “This study will evaluate the efficacy, safety and pharmacokinetics (PK) of VX-147 in participants with apolipoprotein L1 (APOL1)-mediated focal segmental glomerulosclerosis (FSGS).”
> “A Phase 2a, Open-label, Single-arm, 2-Part Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis”

Source: [ClinicalTrials.gov NCT04340362](https://clinicaltrials.gov/study/NCT04340362)

<a id="topic-3.1.2.1-2"></a>

#### Primary, secondary, and exploratory objectives in the protocol

> “To evaluate the ability of VX-147 to reduce proteinuria”
> “To evaluate the safety and tolerability of VX-147”
> “To characterize the PK of VX-147”
> “To evaluate the change in proteinuria after stopping administration of VX-147”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="topic-3.1.2.1-3"></a>

#### Aim of part A and part B in the published report

> “Part A of the phase 2a study was designed to evaluate the ability of inaxaplin to reduce proteinuria.”
> “After the completion of inaxaplin treatment in part A, participants had the option to enroll in part B, which was designed to explore the percent change in proteinuria for up to 12 weeks after the completion of treatment in part A.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.1-4"></a>

#### Proof-of-concept purpose stated in the protocol

> “This study is a Phase 2a proof-of-concept study designed to assess the efficacy effects, safety, and pharmacokinetics (PK) of VX-147 in subjects with APOL1-mediated FSGS.”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="heading-3.1.2.2"></a>

### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

#### Study dates and status in the ClinicalTrials.gov record

> “Study Start (Actual) 2020-06-08”
> “Primary Completion (Actual) 2021-11-11”
> “Study Completion (Actual) 2021-12-09”
> “Results First Posted 2023-07-10”

Source: [ClinicalTrials.gov NCT04340362](https://clinicaltrials.gov/study/NCT04340362)

<a id="topic-3.1.2.2-2"></a>

#### Registered locations

> “This study has 44 locations”

Source: [ClinicalTrials.gov NCT04340362](https://clinicaltrials.gov/study/NCT04340362)

<a id="topic-3.1.2.2-3"></a>

#### Sites, countries, and enrollment period in the published report

> “We then conducted a two-part, single-group, open-label, phase 2a clinical study (VX19-147-101) at 12 sites in France, the United Kingdom, and the United States.”
> “Study enrollment began in September 2020 and was completed in August 2021.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.2-4"></a>

#### Other study identifiers

> “VX19-147-101”
> “2020-000185-42 ( EudraCT Number )”

Source: [ClinicalTrials.gov NCT04340362](https://clinicaltrials.gov/study/NCT04340362)

<a id="heading-3.1.2.3"></a>

### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

#### Single-group, open-label, two-part design

> “We then conducted a two-part, single-group, open-label, phase 2a clinical study (VX19-147-101) at 12 sites in France, the United Kingdom, and the United States.”
> “Participants were enrolled into one of two groups on the basis of the degree of proteinuria (nephrotic or subnephrotic range) at screening and received inaxaplin treatment for 13 weeks (15 mg once daily for 2 weeks, followed by 45 mg once daily for 11 weeks) (Fig. S2).”
> “A safety follow-up visit was required 28 days (within a window of ±7 days) after the receipt of the last dose of inaxaplin.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.3-2"></a>

#### Design details in the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Primary purpose | “Treatment” |
| Allocation | “N/A” |
| Interventional model | “Single Group Assignment” |
| Masking | “None (Open Label)” |
| Phase | “Phase 2” |
| Enrollment | “16” |

Source: [ClinicalTrials.gov NCT04340362](https://clinicaltrials.gov/study/NCT04340362)

<a id="topic-3.1.2.3-3"></a>

#### Cohorts defined by proteinuria at screening in the protocol

> “This is a single-arm, open-label, 2-part study. In Part A, subjects will receive VX-147 at a dosage of 15 mg once daily (qd) for 2 weeks and VX-147 at a dosage of 45 mg qd for 11 weeks.”
> “Cohort 1 includes up to 10 subjects with UPCR approximately ≥3 g/g and <10 g/g and eGFR approximately ≥30 mL/min/1.73 m2. Optional Cohort 2 includes approximately 10 subjects with UPCR approximately ≥0.8 g/g and <2.7 g/g and eGFR approximately ≥30 mL/min/1.73 m2.”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="topic-3.1.2.3-4"></a>

#### Part B off-treatment follow-up

> “After completing Part A, subjects will be followed for up to 12 weeks in Part B (optional) for evaluation of proteinuria off treatment if they consent to do so.”
> “All subjects are required to complete a SFUV at 28 (± 7) days after the last dose of study drug. The SFUV may occur while a subject is participating in Part B.”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="topic-3.1.2.3-5"></a>

#### Rationale for omitting a placebo group and for the 13-week duration

> “A placebo arm was not included because FSGS is a rare, severe disease with a very low likelihood of spontaneous remission.”
> “The duration of 13 weeks for this study was selected to allow the maximum treatment time supported by nonclinical data.”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="topic-3.1.2.3-6"></a>

#### Partially decentralized conduct

> “The present phase 2a clinical study was designed as a partially decentralized study in order to minimize the burden to participants. With our study design, participants had the option to complete assessments on-site or at home with a visiting nurse, a factor that enabled successful completion of the study, especially during the coronavirus disease 2019 pandemic.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.3-7"></a>

#### Study design and oversight

> “The study was designed by the sponsor in collaboration with the steering committee.”
> “Data collection was performed by the sponsor and the VX19-147-101 Study Group; data analysis was performed by the sponsor in collaboration with the steering committee.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="heading-3.1.2.4"></a>

### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

#### Key eligibility criteria in the published report

> “We enrolled adult participants 18 to 65 years of age who had a body weight of more than 50 kg, a body-mass index (the weight in kilograms divided by the square of the height in meters) of 18.0 to 40.0, biopsy-proven focal segmental glomerulosclerosis, two APOL1 variants (G1 and G1, G2 and G2, or G1 and G2), and nephrotic- or subnephrotic-range proteinuria.”
> “Nephrotic-range proteinuria was defined as a urinary protein-to-creatinine ratio (with protein and creatinine both measured in grams) of at least 2.7 and less than 10, and subnephrotic-range proteinuria as a urinary protein-to-creatinine ratio of at least 0.7 and less than 2.7.”
> “All the participants had an estimated glomerular filtration rate (GFR) of at least 27 ml per minute per 1.73 m2 of body-surface area (on the basis of the 2009 Chronic Kidney Disease Epidemiology Collaboration estimating equation for estimated GFR, which includes a coefficient for race).”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.4-2"></a>

#### APOL1 genotyping assay

> “APOL1 genotyping was performed with the use of in vitro diagnostic assay developed by Vertex Pharmaceuticals (the sponsor) and LabCorp. This assay consists of two real-time polymerase-chain-reaction assays that use Taqman to detect the G1 and G2 variants in whole-blood samples.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.4-3"></a>

#### Key inclusion and exclusion criteria in the ClinicalTrials.gov record

> “APOL1 genotype of G1/G1, G2/G2, or G1/G2”
> “FSGS diagnosed by kidney biopsy”
> “Evidence of non-APOL1-mediated FSGS”
> “Participants with known sickle cell disease”
> “Solid organ or Bone marrow transplant”
> “18 Years to 65 Years (Adult, Older Adult )”

Source: [ClinicalTrials.gov NCT04340362](https://clinicaltrials.gov/study/NCT04340362)

<a id="topic-3.1.2.4-4"></a>

#### Inclusion criteria in the protocol: biopsy, stable background therapy, eGFR, and UPCR

> “FSGS diagnosed by kidney biopsy, with the exception of the tip variant, as confirmed through the eligibility review process.”
> “Subjects who are on low-dose corticosteroids (prednisone ≤ 10 mg per day or prednisone equivalent) or on an allowed immunosuppressant (i.e. tacrolimus, mycophenolate, or cyclosporine) must be on a stable dose for 28 days before screening.”
> “Estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2 (±10%) based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.”
> “Subjects with eGFR ≥30 (±10%) to <40 mL/min/1.73 m2 must have tubulointerstitial fibrosis ≤50% or described as no, mild, or moderate on their kidney biopsy.”
> “A UPCR ratio of ≥3 g/g (±10%) and <10 g/g in the first morning void on 3 measurements collected on at least 3 separate days within a 7-day period, during the Screening Period.”
> “A UPCR ratio of ≥0.8 g/g (±10%) and <2.7 g/g in the first morning void on 3 measurements collected on at least 3 separate days within a 7-day period, during the Screening Period.”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="topic-3.1.2.4-5"></a>

#### Exclusion criteria in the protocol: non-APOL1 causes of FSGS and other conditions

> “FSGS occurring in a subject with known sickle cell disease.”
> “Known genetic mutation other than APOL1 G1 or G2 that is associated with FSGS.”
> “Positive serology for human immunodeficiency virus-1 (HIV-1) or human immunodeficiency virus-2 (HIV-2).”
> “Kidney biopsy showing the tip variant of FSGS, as assessed by the eligibility review process.”
> “Screening blood pressure ≥160 mm Hg (systolic) or ≥100 mm Hg (diastolic), based on the average of 3 measurements.”
> “Plan to travel to countries where sleeping sickness is endemic, from the Screening Visit through 1 week after the last dose of study drug.”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="heading-3.1.2.5"></a>

### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

#### Inaxaplin dosing regimen

> “Participants received inaxaplin daily for 13 weeks (15 mg for 2 weeks and 45 mg for 11 weeks) along with standard care.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.5-2"></a>

#### Intervention in the ClinicalTrials.gov record

> “All participants received VX-147 at a dosage of 15 mg once daily (qd) for 2 weeks and VX-147 at a dosage of 45 mg qd for 11 weeks.”
> “Tablets for oral administration.”

Source: [ClinicalTrials.gov NCT04340362](https://clinicaltrials.gov/study/NCT04340362)

<a id="topic-3.1.2.5-3"></a>

#### Administration instructions in the protocol

> “VX-147 will be administered as 15 mg tablets, orally, as shown in Table 3-2.”
> “Study drug may be taken with or without food.”
> “Subjects will swallow the study drug whole, with a full glass of water and will not chew it before swallowing.”
> “No dose modifications are allowed.”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="topic-3.1.2.5-4"></a>

#### Rationale for the 15 mg and 45 mg doses

> “The 2-week duration for the 15 mg qd dose was selected based on an exposure-response model suggesting that a measurable decrease in proteinuria may be observed after 2 weeks of dosing.”
> “A high dose of 45 mg once daily is selected to maximize the probability of reduction in proteinuria over the 11-week dosing period.”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="topic-3.1.2.5-5"></a>

#### Background standard care

> “Participants were required to continue taking stable doses of standard-care medications from at least 28 days before commencing inaxaplin through follow-up. Such medications could include, but were not limited to, systemic glucocorticoids (prednisone at a dose of ≤10 mg per day or equivalent), immunosuppressants (tacrolimus, cyclosporine, or mycophenolate mofetil), and renin–angiotensin–aldosterone inhibitors.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.5-6"></a>

#### Restricted medications and foods in the protocol

> “Moderate and strong CYP3A4 inhibitors or inducers, including consumption of herbal medications (e.g., St. John’s Wort)”
> “None allowed within 14 days before the first dose of the study drug”
> “Grapefruit, grapefruit juice, pomelos, orange marmalade, Seville/blood oranges”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="topic-3.1.2.5-7"></a>

#### Travel restriction

> “As a condition of participation in the study, we prohibited travel during the study to countries where African sleeping sickness (African trypanosomiasis) is endemic.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="heading-3.1.2.6"></a>

### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

#### 3.1.2.6.1 Rationale for Using Percent Change in UPCR as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

##### Primary and secondary outcomes

> “The primary efficacy outcome was the percent change from the baseline urinary protein-to-creatinine ratio at week 13. Secondary outcomes included safety and pharmacokinetics. The safety analysis was based on adverse events, clinical laboratory values, standard 12-lead electrocardiograms, and vital signs.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.6.1-2"></a>

##### Registered primary and secondary outcome measures

> “Percent Change From Baseline in UPCR”
> “From Baseline up to Week 13”
> “Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)”
> “Maximum Observed Concentration (Cmax) of VX-147”
> “Observed Pre-dose Concentration (Ctrough) of VX-147”
> “Area Under the Concentration Time-curve From 0 to 24 Hours (AUC0-24hr) of VX-147”

Source: [ClinicalTrials.gov NCT04340362](https://clinicaltrials.gov/study/NCT04340362)

<a id="topic-3.1.2.6.1-3"></a>

##### Exploratory endpoints in the protocol

> “Percent change from baseline in urine albumin-to-creatinine ratio (UACR) at Week 13”
> “Change from baseline in patient-reported outcome (PRO) Short Form Health Survey 36 (SF-36) over time during the Treatment Period”
> “Percent change from baseline in UPCR at the end of the Off-treatment Follow-up Period”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="topic-3.1.2.6.1-4"></a>

##### Sponsor rationale for UPCR as the primary endpoint and its measurement

> “Percent change from baseline in UPCR at Week 13 was chosen as the primary endpoint because proteinuria is a characteristic feature of FSGS and 1 of its main prognostic factors.”
> “As UPCR is variable within an individual, 3 samples will be taken during screening, Week 5, Week 9, and Week 13; and the average of the 3 values will be used to determine baseline, Week 5, Week 9, and end-of-treatment UPCR values, respectively.”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="topic-3.1.2.6.1-5"></a>

##### Proteinuria and progression to end-stage kidney disease

> “Among patients with CKD, including those with two APOL1 variants, the degree of proteinuria is directly associated with the likelihood of progression to end-stage kidney disease, and several agents that reduce proteinuria have been shown to attenuate CKD progression and reduce the risk of cardiovascular events.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.6.1-6"></a>

##### Threshold for a clinically meaningful reduction in proteinuria

> “A reduction in proteinuria or albuminuria of more than 40% is considered to be clinically meaningful on the basis of data from nearly 30,000 patients, in whom a 30% reduction in albuminuria translated to a 27% reduction in the risk of a composite clinical end point of end-stage kidney disease, an estimated GFR below 15 ml per minute per 1.73 m2, or a doubling of the serum creatinine level (57% reduction in the estimated GFR).”
> “Collectively, these data provide a rationale to test the hypothesis that with a longer treatment period, inaxaplin therapy may prevent or slow progression to end-stage kidney disease.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.6.1-7"></a>

##### Placebo response in proteinuric CKD trials

> “In participants who received placebo in placebo-controlled trials involving patients with proteinuric CKD, reductions of up to 15% in the urinary protein-to-creatinine ratio have been observed,37,38 a treatment effect that is much smaller than what we observed in this study.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.6.1-8"></a>

##### Commentary on proteinuria reduction as an endpoint

> “The degree of proteinuria reduction achieved in the phase 2A clinical trial has been shown to be associated with slowing the progression of proteinuric kidney disease and it is unlikely to be an artefact of being enrolled in a clinical trial”

Source: [Gbadegesin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10461697/)

<a id="heading-3.1.2.7"></a>

### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

#### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

##### Planned enrollment in the protocol

> “Up to 10 subjects in Cohort 1 and approximately 10 subjects in optional Cohort 2”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="topic-3.1.2.7.1-2"></a>

##### Sample size based on precision of the estimate

> “The sample size was selected on the basis of the precision of the expected estimator. Assuming a standard deviation of 0.672 (in log scale), we calculated that a sample size of 10 would provide the study with a precision of 0.294 (in log scale) for the estimation of the geometric mean percent change from baseline in the urinary protein-to-creatinine ratio.”
> “Although we did not determine a sample size on the basis of power calculations, we anticipated a relatively large reduction in proteinuria and believed that the selected sample size on the basis of precision estimation would be sufficient to determine the range of proteinuria reduction that could inform the design of subsequent, longer-term, placebo-controlled trials.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.7.1-3"></a>

##### Participants enrolled and analyzed

> “Sixteen participants were enrolled in the phase 2a study.”
> “Among the 16 participants, 3 did not have at least 80% adherence to treatment and were therefore not included in the primary efficacy analyses, as prespecified in the statistical analysis plan (see the Supplementary Appendix).”
> “As compared with the baseline reduction in proteinuria that was observed at the end of part A of the study, in the exploratory part B of the study (in which data from nine participants were assessed), the mean urinary protein-to-creatinine ratio increased from −47.6% to −30.1% at week 4.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.7.1-4"></a>

##### Participants by cohort in the posted results

| Measure | Quoted record |
| --- | --- |
| Enrollment (actual) | “16” |
| Started | “16” |
| Cohort 1 | “3” |
| Cohort 2 | “13” |
| AUC0-24hr, overall number of participants analyzed | “13” |

Source: [ClinicalTrials.gov NCT04340362 results](https://clinicaltrials.gov/study/NCT04340362?tab=results)

<a id="heading-3.1.2.7.2"></a>

#### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

##### Primary efficacy analysis restricted to participants with at least 80% adherence

> “As prespecified in the statistical analysis plan (which is available with the protocol), the primary efficacy analysis included all the participants who had at least 80% adherence to inaxaplin treatment. We also report the results of efficacy analyses that included all the participants regardless of treatment adherence.”
> “Safety analyses included all the participants who received at least one dose of inaxaplin; safety data were summarized with the use of descriptive statistics.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.7.2-2"></a>

##### Analysis sets defined in the statistical analysis plan

> “The Full Analysis Set (FAS) will include all subjects who received at least 1 dose of study drug in the Treatment Period and with at least 1 post-baseline efficacy assessment.”
> “The Follow-up Set will include all subjects who entered the Off-treatment Follow-up Period (Part B) and have at least 1 efficacy assessment in that period.”
> “The Safety Set will include all subjects who received at least 1 dose of study drug.”
> “Subjects non-compliant with study drug will not be included in the analysis.”

Source: [Vertex Pharmaceuticals VX19-147-101 statistical analysis plan (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/SAP_001.pdf)

<a id="topic-3.1.2.7.2-3"></a>

##### Analysis populations in the posted results

> “All participants who received at least one dose of the study drug during the treatment period were included in the baseline analysis.”
> “The PK set included all those who received at least 1 dose of study drug.”

Source: [ClinicalTrials.gov NCT04340362 results](https://clinicaltrials.gov/study/NCT04340362?tab=results)

<a id="topic-3.1.2.7.2-4"></a>

##### Statistical methods for the primary endpoint: log-transformed geometric mean percent change

> “We calculated the urinary protein-to-creatinine ratio as the mean of the three values from first-morning void urine samples obtained within a 7-day window. To reduce skewness, we analyzed the percent change from the baseline urinary protein-to-creatinine ratio at week 13 by first log-transforming the data for the ratio before the analyses and then calculating the change from baseline in log-transformed values.”
> “We calculated the geometric mean percent change from the baseline urinary protein-to-creatinine ratio at week 13 and the corresponding two-sided confidence interval by back-transforming the estimated simple mean of the change from baseline in log-transformed data.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.7.2-5"></a>

##### Statistical methods: confidence intervals, multiplicity, and sensitivity analyses in the statistical analysis plan

> “The GMPC from baseline in UPCR at Week 13, GSE (%), along with the corresponding 2-sided 80% CI will be provided. In addition, the corresponding 2-sided 95% CI will be provided for descriptive purposes.”
> “Multiplicity: No multiplicity adjustment will be performed.”
> “There will be no supportive analysis for the primary efficacy endpoint.”
> “No sensitivity analysis for the primary efficacy variable is planned.”

Source: [Vertex Pharmaceuticals VX19-147-101 statistical analysis plan (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/SAP_001.pdf)

<a id="topic-3.1.2.7.2-6"></a>

##### Statistical methods: descriptive safety and pharmacokinetic analyses in the protocol

> “The safety analyses will be descriptive only.”
> “Noncompartmental analyses will be performed, and summary statistics will be provided for VX-147 PK parameters.”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="heading-3.1.2.8"></a>

### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

#### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

##### Participant flow in the posted results

| Milestone | Quoted record |
| --- | --- |
| Started | “16” |
| Cohort 1 | “3” |
| Cohort 2 | “13” |
| Completed | “15” |
| Not completed | “1” |
| Reason not completed | “Withdrawal of consent (not due to adverse event)” |

Source: [ClinicalTrials.gov NCT04340362 results](https://clinicaltrials.gov/study/NCT04340362?tab=results)

<a id="topic-3.1.2.8.1-2"></a>

##### Study parts covered by the posted results

> “This study was planned in 2 parts: Part A (Treatment Period), which consisted of 2 cohorts (i.e., cohort 1 and 2) and Part B (Optional Exploratory Off-treatment Follow-up Period). The primary and secondary efficacy analyses and safety analyses were planned for only Part A.”

Source: [ClinicalTrials.gov NCT04340362 results](https://clinicaltrials.gov/study/NCT04340362?tab=results)

<a id="topic-3.1.2.8.1-3"></a>

##### Exclusion of participants below the adherence threshold and part B participation

> “Among the 16 participants, 3 did not have at least 80% adherence to treatment and were therefore not included in the primary efficacy analyses, as prespecified in the statistical analysis plan (see the Supplementary Appendix).”
> “Finally, although just nine participants entered the optional extension of the study (part B), we were encouraged that the reduction in proteinuria was sustained after the completion of treatment in some participants.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.8.1-4"></a>

##### Company statement on noncompliant participants

> “A total of 16 patients were enrolled in the study. According to the pre-specified statistical analysis plan, three patients who were noncompliant with treatment were not included in the primary efficacy analysis.”

Source: [Vertex Pharmaceuticals press release, phase 2 results (2021)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2-study-vx-147-apol1)

<a id="heading-3.1.2.8.2"></a>

#### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

##### Demographic and clinical characteristics at baseline (Table 1)

| Characteristic | Total (N=16) | Nephrotic-range proteinuria (N=3) | Subnephrotic-range proteinuria (N=13) |
| --- | --- | --- | --- |
| Age, years, mean ±SD | “38.8±14.5” | “45.0±10.5” | “37.3±15.2” |
| Male, no. (%) | “7 (44)” | “1 (33)” | “6 (46)” |
| Female, no. (%) | “9 (56)” | “2 (67)” | “7 (54)” |
| APOL1 genotype G1/G1, no. (%) | “9 (56)” | “3 (100)” | “6 (46)” |
| APOL1 genotype G2/G2, no. (%) | “1 (6)” | “0” | “1 (8)” |
| APOL1 genotype G1/G2, no. (%) | “6 (38)” | “0” | “6 (46)” |
| Body-mass index, mean ±SD | “29.6±6.4” | “32.7±6.4” | “28.9±6.4” |
| Urinary protein-to-creatinine ratio, mean ±SD | “2.08±0.90” | “3.47±1.07” | “1.77±0.49” |
| Estimated GFR, ml/min/1.73 m2, mean ±SD | “51.2±14.0” | “51.4±22.2” | “51.2±12.8” |
| ACE inhibitor ≥28 days before day 1, no. (%) | “8 (50)” | “1 (33)” | “7 (54)” |
| Angiotensin-receptor blocker ≥28 days before day 1, no. (%) | “7 (44)” | “3 (100)” | “4 (31)” |
| Immunosuppressants ≥28 days before day 1, no. (%) | “4 (25)” | “1 (33)” | “3 (23)” |

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.8.2-2"></a>

##### Immunosuppressants taken by participants

> “Immunosuppressants included systemic glucocorticoids. The following medications were taken by participants: prednisone (one participant), mycophenolate mofetil (one), and tacrolimus (two).”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.8.2-3"></a>

##### Baseline UPCR in the efficacy population and similarity across subgroups

> “The mean (±SD) age of the 16 enrolled participants was 38.8±14.5 years, and the mean baseline urinary protein-to-creatinine ratio was 2.08±0.90 among all the participants who had received at least one dose of inaxaplin and 2.21±0.95 among the 13 participants who were evaluable in the efficacy analysis (Table 2).”
> “The baseline characteristics of the participants, including the estimated GFR at baseline and the distribution of standard-care medications, were generally similar among the 3 participants with nephrotic-range proteinuria and the 13 with subnephrotic-range proteinuria and among the 13 participants who were included in the primary analysis and the 3 who were not.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.8.2-4"></a>

##### Race and ethnicity in the posted results

| Characteristic | Cohort 1 (N=3) | Cohort 2 (N=13) |
| --- | --- | --- |
| Black or African American | “3” | “13” |
| White | “0” | “0” |
| Not Hispanic or Latino | “3” | “13” |

Source: [ClinicalTrials.gov NCT04340362 results](https://clinicaltrials.gov/study/NCT04340362?tab=results)

<a id="heading-3.1.2.8.3"></a>

#### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

##### Primary endpoint: percent change from baseline in UPCR at week 13 (Table 2)

| Measure | Total (N=13) | Nephrotic-range proteinuria (N=3) | Subnephrotic-range proteinuria (N=10) |
| --- | --- | --- | --- |
| Mean UPCR at baseline, ±SD | “2.21±0.95” | “3.47±1.07” | “1.84±0.52” |
| Mean UPCR at week 13, ±SD | “1.27±0.73” | “1.83±0.58” | “1.10±0.71” |
| Geometric percent change from baseline at week 13 (95% CI) | “−47.6 (−60.0 to −31.3)” | “−47.7 (−70.1 to −8.5)” | “−47.5(−63.4 to −24.6)” |

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.8.3-2"></a>

##### Primary endpoint in the published abstract

> “Among the 13 participants who were treated with inaxaplin and met the adherence threshold, the mean change from the baseline urinary protein-to-creatinine ratio at week 13 was −47.6% (95% confidence interval, −60.0 to −31.3).”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.8.3-3"></a>

##### Time course of proteinuria reduction

> “The treatment response from baseline was rapid and approximately linear, with a decrease seen by day 15; proteinuria continued to decrease through week 13 (Figure 2B).”
> “Reduction in proteinuria was seen in both the nephrotic- and subnephrotic-range groups (mean change in the urinary protein-to-creatinine ratio, −47.7% and −47.5%, respectively) (Table 2) and was unrelated to background standard-care medications.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.8.3-4"></a>

##### Analysis of all 16 participants regardless of adherence

> “In an analysis that included all 16 participants, regardless of adherence to inaxaplin treatment, the mean change in the urinary protein-to-creatinine ratio at week 13 was −44.0% (95% CI, −56.3 to −28.3); one participant did not have a reduction (Fig. S5).”
> “Although this participant had 100% adherence to treatment, there were no clinical characteristics that appeared to have influenced the lack of treatment response.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.8.3-5"></a>

##### Part B: UPCR after stopping inaxaplin

> “As compared with the baseline reduction in proteinuria that was observed at the end of part A of the study, in the exploratory part B of the study (in which data from nine participants were assessed), the mean urinary protein-to-creatinine ratio increased from −47.6% to −30.1% at week 4. The urinary protein-to-creatinine ratio remained stable for an additional 8 weeks (Fig. S6).”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.8.3-6"></a>

##### Pharmacokinetics: AUC0-24h at week 5 (secondary outcome)

| Measure | Quoted record |
| --- | --- |
| Outcome measure | “Area Under the Concentration Time-curve From 0 to 24 Hours (AUC0-24hr) of VX-147” |
| Time frame | “Pre-dose and at 0.25, 0.5, 1, 2, 4, 12 and 24 hours Post-dose on Week 5” |
| Overall number of participants analyzed | “13” |
| Mean (standard deviation), h*mcg/mL | “15.3(6.37)” |

Source: [ClinicalTrials.gov NCT04340362 results](https://clinicaltrials.gov/study/NCT04340362?tab=results)

<a id="topic-3.1.2.8.3-7"></a>

##### Company statement of the primary endpoint result

> “In the 13 evaluable patients, treatment with VX-147 on top of standard of care resulted in a rapid, statistically significant and clinically meaningful mean change in proteinuria from baseline of -47.6% (95% CI: -60.0%, -31.3%) following 13 weeks of treatment.”
> “Results were consistent regardless of baseline proteinuria or background therapy.”

Source: [Vertex Pharmaceuticals press release, phase 2 results (2021)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2-study-vx-147-apol1)

<a id="heading-3.1.2.8.4"></a>

#### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.2.8.4-1"></a>

##### SF-36 planned as an exploratory endpoint

> “Change from baseline in patient-reported outcome (PRO) Short Form Health Survey 36 (SF-36) over time during the Treatment Period”
> “Change in SF-36 from baseline over the study treatment period will be assessed as an exploratory outcome. SF-36 is a patient-reported generic measure of health status.”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="topic-3.1.2.8.4-2"></a>

##### SF-36 results

No evidence found.

<a id="heading-3.1.2.8.5"></a>

#### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

##### Overview of adverse events

> “Among the 16 participants who received at least one dose of inaxaplin, 15 (94%) had at least one adverse event. All the adverse events were mild or moderate in severity; there were no treatment discontinuations due to adverse events. Adverse events that occurred in more than 2 participants were headache, back pain, and nausea (Table 3).”
> “Three participants had adverse events that were considered by the investigator to be possibly related to inaxaplin (2 participants with headache and 1 participant with headache, abdominal distension, dyspepsia, and back pain).”
> “Two serious adverse events occurred in 1 participant: deep-vein thrombosis and uterine leiomyoma; neither event was considered by the investigator to be related to inaxaplin.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.8.5-2"></a>

##### Adverse events (Table 3)

| Event, no. (%) | Total (N=16) | Nephrotic-range proteinuria (N=3) | Subnephrotic-range proteinuria (N=13) |
| --- | --- | --- | --- |
| Any adverse event | “15 (94)” | “3 (100)” | “12 (92)” |
| Mild | “7 (44)” | “1 (33)” | “6 (46)” |
| Moderate | “8 (50)” | “2 (67)” | “6 (46)” |
| Serious adverse event | “1 (6)” | “0” | “1 (8)” |
| Headache | “4 (25)” | “1 (33)” | “3 (23)” |
| Back pain | “3 (19)” | “0” | “3 (23)” |
| Nausea | “3 (19)” | “1 (33)” | “2 (15)” |
| Decrease in blood bicarbonate level | “2 (12)” | “0” | “2 (15)” |
| Diarrhea | “2 (12)” | “1 (33)” | “1 (8)” |
| Dizziness | “2 (12)” | “0” | “2 (15)” |
| Dyspepsia | “2 (12)” | “0” | “2 (15)” |
| Fatigue | “2 (12)” | “0” | “2 (15)” |

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.8.5-3"></a>

##### Laboratory values, electrocardiograms, vital signs, and eGFR

> “There were no clinically significant safety findings in other clinical or laboratory assessments, including the hemoglobin level, liver-enzyme levels, total bilirubin level, lipid concentrations, electrocardiograms, or vital signs. Participants had a stable estimated GFR and blood pressure throughout the study (Fig. S7 and Table S4).”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.8.5-4"></a>

##### Deaths, serious adverse events, and other adverse events in the posted results

| Measure, affected / at risk (%) | Cohort 1 | Cohort 2 | Total |
| --- | --- | --- | --- |
| All-cause mortality | “0/3 (0.00%)” | “0/13 (0.00%)” | “0/16 (0.00%)” |
| Serious adverse events, total | “0/3 (0.00%)” | “1/13 (7.69%)” | “1/16 (6.25%)” |
| Other (not including serious) adverse events, total | “3/3 (100.00%)” | “12/13 (92.31%)” | “15/16 (93.75%)” |

Source: [ClinicalTrials.gov NCT04340362 results](https://clinicaltrials.gov/study/NCT04340362?tab=results)

<a id="topic-3.1.2.8.5-5"></a>

##### Adverse events in investigations and cardiac disorders in the posted results

| Event | Total, affected / at risk (%) |
| --- | --- |
| Blood bicarbonate decreased | “2/16 (12.50%)” |
| Blood creatine phosphokinase increased | “1/16 (6.25%)” |
| Electrocardiogram ST segment depression | “1/16 (6.25%)” |
| Gamma-glutamyltransferase increased | “1/16 (6.25%)” |
| Transaminases increased | “1/16 (6.25%)” |
| Palpitations | “1/16 (6.25%)” |

Source: [ClinicalTrials.gov NCT04340362 results](https://clinicaltrials.gov/study/NCT04340362?tab=results)

<a id="topic-3.1.2.8.5-6"></a>

##### Company statement on safety

> “There were no treatment discontinuations due to adverse events (AEs), and there were no serious adverse events considered related to study drug. All AEs were mild or moderate in severity. The most common AEs (occurring in > 15% of subjects) were headache, back pain and nausea.”

Source: [Vertex Pharmaceuticals press release, phase 2 results (2021)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2-study-vx-147-apol1)

<a id="heading-3.1.2.9"></a>

### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

#### Summary: study limitations

VX19-147-101 was a single-group, open-label study without a placebo group; the protocol states that a placebo arm was omitted because of a “very low likelihood of spontaneous remission”. Sixteen participants were enrolled, and the primary analysis included the 13 participants with at least 80% adherence; the planned sample size of 10 was chosen for the precision of the geometric mean estimate, without a power calculation. Treatment lasted 13 weeks, and the off-treatment follow-up (part B) included 9 participants. The primary endpoint was the percent change from baseline in the urinary protein-to-creatinine ratio at week 13, and the secondary endpoints were safety and pharmacokinetics. Eligibility required biopsy-proven focal segmental glomerulosclerosis, two APOL1 variants, age 18 to 65 years, and an estimated GFR of at least 30 mL/min/1.73 m2 (±10%), so other APOL1-mediated kidney disease phenotypes were not studied; only 3 participants had nephrotic-range proteinuria. All 16 participants were Black or African American and were enrolled at sites in France, the United Kingdom, and the United States. The protocol listed SF-36 as an exploratory endpoint, and no SF-36 results were located in the published report or the posted results.

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396); [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf); [ClinicalTrials.gov NCT04340362 results](https://clinicaltrials.gov/study/NCT04340362?tab=results)

<a id="topic-3.1.2.9-2"></a>

#### Limitations stated by the investigators

> “Our study has certain limitations. It was small, short in duration, and not placebo-controlled.”
> “Although only three participants with nephrotic-range proteinuria were enrolled in this study, the results in these participants appeared to be consistent with those observed in participants who had less-severe proteinuria.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.9-3"></a>

#### Other APOL1-mediated kidney disease phenotypes not studied

> “The effects of inaxaplin therapy in this short-term clinical study involving participants with two APOL1 variants and biopsy-proven focal segmental glomerulosclerosis (a severe, rapidly progressive form of proteinuric CKD) remain to be studied in persons with two APOL1 variants and other types of proteinuric CKD, such as hypertensive kidney disease.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.9-4"></a>

#### Commentary: lack of randomization, population, and endpoint

> “First, this is not a randomized control trial, there is therefore a need for a phase 3 clinical trial of inaxaplin + standard of care versus placebo + standard of care before clinical use.”
> “Second, the study was carried out in a small population of participants from Europe and North America.”
> “This point is especially important since Africans living in Africa were not part of this study.”
> “Third, reduction in proteinuria was used as the primary end point for this study”

Source: [Gbadegesin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10461697/)

Additional sources: [Williams and Ingelfinger (2023)](https://pubmed.ncbi.nlm.nih.gov/36920762/); [Soler et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37379147/)

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
